Antimicrobial interventions for the management of diabetic foot infections

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 2, 2005, Pages 263-273

  Senneville, Eric ^a  

^a Dron Hospital   (France)

Author keywords

Antimicrobial agents; Diabetic foot infections; Osteomyelitis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFALEXIN; CEFOXITIN; CEFTIZOXIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; DALFOPRISTIN PLUS QUINUPRISTIN; DICLOXACILLIN; FLUCLOXACILLIN; FUSIDIC ACID; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METICILLIN; NAFCILLIN; OFLOXACIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PRISTINAMYCIN; RIFAMPICIN; SULTAMICILLIN; TIMENTIN; TOBRAMYCIN; TROVAFLOXACIN; UNINDEXED DRUG;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; BACTEROIDES; BONE BIOPSY; CITROBACTER; CLINICAL TRIAL; CONVULSION; COOPERATION; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC FOOT; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; ENTEROBACTER; ESCHERICHIA COLI; FOOT AMPUTATION; GASTROINTESTINAL DISEASE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITALIZATION; HUMAN; INDIVIDUALIZATION; KIDNEY DISEASE; MEDICAL SPECIALIST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA; ORTHOPEDIC SURGERY; OSTEOMYELITIS; PATIENT CARE; PERIPHERAL NEUROPATHY; PRESCRIPTION; PROTEUS; PROVIDENCIA; PSEUDOMONAS; RELIABILITY; REVIEW; SERRATIA; SKIN INFECTION; SKIN ULCER; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; STREPTOCOCCUS; SYSTEMATIC REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; DISEASE MANAGEMENT; HUMANS; SOFT TISSUE INFECTIONS;

EID: 14544305041     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.2.263     Document Type: Review

References (61)

1. LIPSKY BA. Infectious problems of the foot in diabetic patients. In: The diabetic foot (6th edn). Bowker JH, Pfeifer MA (Eds), Mosby, St. Louis, USA (2001):467-480.
2. CUNHA BA: Antibiotic selection for diabetic foot infections: a review. J. Foot Ankle Surg. (2000) 39:253-257.
3. JAEGEBLAD G, APELQVIST J, NYBERG P, BERGER B: The diabetic foot: from ulcer to multidisciplinary team approach; a process analysis. 3rd International Symposium of the Diabetic Foot, Noordwijkerhout, The Netherlands (1998) (Abstract P87).
4. VENKATESAN P, LAWN S, MACFARLANE RM, FLETCHER EM, FINCH RG, JEFFCOATE WJ: Conservative management of osteomyelitis in the feet of diabetic patients. Diabet. Med. (1997) 14:487-490.
5. PITTET D, WYSSA B, HERTER-CLAVEL C, KURSTEINER K, VAUCHER J, LEW DP: Outcome of diabetic foot infections treated conservatively: a retrospective cohort study with long-term follow-up. Arch. Intern. Med. (1999) 159:851-856.
6. SENNEVILLE E, YAZDANPANAH Y, CAZAUBIEL M et al.: Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis. J. Antimicrob. Chemother. (2001) 48 927-930.
7. TENTOLOURIS N, JUDE EB, SMIRNOF I, KNOWLES EA, BOULTON AJM: Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet. Med. (1999) 16:767-771.
8. The Diabetic Foot: Proceedings of the Third International Symposium on the Diabetic Foot, 5-8 May 1999, Noordwijkerhout, The Netherlands. Diabetes Metab. Res. Rev. (2000) 16 Suppl.):S1-S92.
9. The Diabetic Foot: Procceedings of the Fourth International Symposium on the Diabetic Foot, 22-24 May 2003, Noordwijkerhout, The Netherlands. Diabetes Metab. Res. Rev. (2004) 20 Suppl.):S1-S95.
10. HUGHES CA, JOHNSON CC, BAMBERGER DM et al.: Treatment and long-term follow-up of foot infections in patients with diabetes or ischemia: a randomized, prospective, double-blind comparison of cefoxitin and ceftizoxime. Clin. Ther. (1987) 10(Suppl. A):36-49.
11. FILE TM, TAN JS: Amdinocillin plus cefoxitin versus cefoxitin alone in therapy of mixed soft tissue infections (including diabetic foot infections). Am. J. Med. (1983) 80(Suppl.):100-105.
12. ANANIA WC, CHINKES SL, ROSEN RC, TURNER PR, HELFAND AE: A selective clinical trial of ceftizoxime. J. Am. Podiatr. Med. Assoc. (1987) 77:648-652.
13. GRAYSON ML, GIBBONS GW, HABERSHAW GM et al.: Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin. Infect. Dis. (1994) 18:683-693.
14. AKOVA M, ÖZCEBE O, GÜLLÜ ÜNAL S et al.: Efficacy of sulbactam-ampicillin for the treatment of severe diabetic foot infections. J. Chemother. (1996) 8:284-289.
15. ZEILLEMAKER AM, VELDKAMP KE, VAN KRAAIJ MG, HOEKSTRA JBL, VAN PAPENDRECHT AA, DIPERSLOOT RJ: Piperacillin/tazobactam therapy for diabetic foot infection. Foot Ankle Int. (1998) 19:169-172.
16. GRAHAM DR, TALAN DA, NICHOLS RL et al.: Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin. Infect. Dis. (2002) 35:381-389.
17. PETERSON LR, LISSACK LM, CANTER K, FASCHING CE, CLABOTS C, GERDING DN: Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. Am. J. Med. (1989) 86:801-808.
18. SESIN GP, PASZKO A, O'KEEFE EO: Oral clindamycin and ciprofloxacin therapy for diabetic foot infections. Pharmacotherapy (1990) 10:154-156.
19. BEAM TR, GUTIERREZ I, POWELL S et al.: Prospective study of the efficacy and safety of oral and intravenous ciprofloxacin in the treatment of diabetic foot infections. Rev. Infect. Dis. (1989) 11(Suppl. 5):S11-S63.
20. DIAMANTOPOULOS EJ, HARITOS D, YFANDI G et al.: Management of severe diabetic foot infections. Exp. Clin. Endocrinol. Diabetes (1998) 106:346-352.
21. CALANDRA GB, RAUPP W, BROWN KR: Imipenem/cilastatin treatment of lower extremity skin and soft tissue infections in diabetics. Scand. J. Infect. Dis. Suppl. (1987) 52:15-19.
22. LIPSKY BA, ITANI K, NORDEN C, and the LINEZOLID DIABETIC FOOT INFECTIONS STUDY GROUP: Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin. Infect. Dis. (2004) 38:17-24.
23. NORDEN C, SHINNERS E, NIEDERITTER K: Clindamycin treatment of experimental chronic osteomyelitis due to Staphylococcus aureus. J. Infect. Dis. (1986) 153:956-959.
24. HARDING I, MACGOWAN A, WHITE L, DARLEY E, REED V: Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob. Chemother. (2000) 45:835-841.
25. LIPSKY B: A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab. Res. Rev. (2004) 20(Suppl.):S68-S77.
26. CHANTELAU E, TANUDJAJA T, ALTENHÖFER F, ERSANLI Z, LACIGOVA S, METZGER C: Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial. Diab. Med. (1996) 13:156-159.
27. TENNVALL GR, APELQVIST J, ENEROTH M: Costs of deep foot infections. An analysis of factors determining treatment costs. Pharmacoeconomics (2000) 18:225-238.
28. LIPSKY BA: Evidence-based antibiotic therapy of diabetic foot infections. FEMS Immunol. Med. Microbiol. (1999) 26:267-276.
29. WILSON RM: Neutrophil function in diabetes. Diab. Med. (1986) 3:509-512.
30. WHEAT LJ, ALLEN SD, HENRY M et al.: Diabetic foot infections: bacteriologic analysis. Arch. Intern. Med. (1986) 146: 1935-1940.
31. SAPICO FL, WITTE JL, CANAWATI HN, MONTGOMERIE JZ, BESSMAN AW: The infected foot of the diabetic patient: quantitative microbiology and analysis of clinical features. Rev. Infect. Dis. (1984) 6 Suppl. 1):171-176.
32. GERDING DN: Foot infections in diabetic patients: the role of anaerobes. Clin. Infect. Dis. (1995) 20(Suppl. 2):S283-288.
33. PATHARE N, BAL A, TALVALKAR G, ANTANI D: Diabetic foot infections: a study of microorganisms associated with the different Wagner grades. Ind. Pathol. Microbiol. (1998) 41(4 ):437-441.
34. LIPSKY BA, BAKER PD, LANDON GC, FERNAU R: Antibiotic therapy for diabetic foot infections: comparison of two parental-to-oral regimens. Clin. Infect. Dis. (1997) 24:643-648.
35. DANG C, PRASAD Y, JUDE E et al.: Methicilin-resistant Staphylococcus aureus in the diabetic clinic: a worsening problem. Diab. Med. (2003) 20:159-161.
36. GRAYSON ML, GIBBONS GW, BALOGH K, LEVIN E, KARCHMER AW. Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. JAMA (1995) 273:721-723.
37. LIPSKY BA: Osteomyelitis of the foot in diabetic patients. Clin. Infect. Dis. (1997) 25:1318-1326.
38. NEWMAN LG, WALLER J, PALESTRO CJ et al.: Unsuspected osteomyelitis in diabetic foot ulcers: diagnosis and monitoring by leukocyte scanning with indium 111 oxyquinoline. JAMA (1991) 266 1246-1251.
39. SUTTON P, HARLEY J, JACOBSON A, LIPSKY BA: Diagnosing osteomyelitis with percutaneous bone biopsy in patients with diabetes and foot infection. In: Proceedings of the 38th Annual Meeting of the Infectious Diseases Society of America (New Orleans). Infectious Diseases Society of America, Alexandria, VA, USA (2000) (Abstract 30).
40. LAVERY LA, SARIAYA M, ASHRY H, HARKLESS LB: Microbiology of osteomyelitis in diabetic foot infections. J. Foot Ankle Surg. (1995) 34:61-64.
41. VAN BAAL J: Surgical Treatment of the Infected Diabetic Foot. Clin. Infect. Dis. (2004) 20(Suppl.):S123-S128.
42. HA VAN G, SINEY H, DANAN JP, SACHON C, GRIMALDI A: Treatment of osteomyelitis in the diabetic foot: contribution of conservative surgery. Diabetes Care (1996) 19:1257-1260.
43. TAN JS, FRIEDMAN NM, HAZELTON-MILLER C, FLANAGAN JP, FILE TM Jr: Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation? Clin. Infect. Dis. (1996) 23 286-291.
44. KERSTEIN MD, WELTER V, GAHTAN V, ROBERTS AB: Toe amputation in the diabetic patient. Surgery (1997) 122:546-547.
45. ROEDER B, VAN GILS CC, MALING S: Antibiotic beads in the treatment of diabetic pedal osteomyelitis. J. Foot Ankle Surg. (2000) 39:124-130.
46. PECK KR, SON DW, SONG JH, KIM S, OH MD, CHOE KW: Enhanced neutrophil functions by recombinant human granulocyte colony-stimulating factor in diabetic patients with foot infections in vitro. J. Korean Med. Sci. (2001) 16:39-44.
47. DE LALLA F, PELLIZZER G, STRAZZABOSCO M et al.: Randomized prospective controlled trial of recombinant granulocyte-colony stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob. Agents Chemother. (2001) 45 1094-1098.
48. GOUGH A, CLAPPERTON M, ROLANDO N, FOSTER AVM, PHILPOTT-HOWARD J, EDMONDS ME: Randomized placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infections. Lancet (1997) 350:855-859.
49. BAKKER DJ: Hyperbaric oxygen therapy and the diabetic foot. Diabetes Metab. Res. Rev. (2000) 16(Suppl. 1):S55-S58.
50. LEE SS, CHEN CY, CHAN YS, YEN CY, CHAO EK, UENG SWN: Hyperbaric oxygen in the treatment of diabetic foot infection. Chang Gung Med. J. (1997) 20:17-22.
51. WUNDERLICH RP, PETERS EJG, LAVERY L: Systemic hyperbaric oxygen therapy: lower-extremity wound healing and the diabetic foot. Diabetes Care (2000) 23:1551-1555.
52. RAYMAKERS JT, HOUBEN AJ, VAN DE HEYDEN JJ, TORDOIR JH, KITSLAAR PJ, SCHAPER NC: The effect of diabetes and severe ischaemia on the penetration of ceftazidime into tissues of the limb. Diabet. Med. (2001) 18:229-234.
53. MULLER M, BRUNNER M, HOLLENSTEIN U et al.: Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non insulin-dependent diabetes mellitus patients. Antimicrob. Agents Chemother. (1999) 43:2056-2058.
54. WITSO E, PERSEN L, LOSETH K, BERGH K: Adsorption and release of antibiotics from morselized cancellous bone: in vitro studies of 8 antibiotics. Acta Orthop. Scand. (1999) 70(3):298-304.
55. DRANCOURT M, STEIN A, ARGENSON JN, ZANNIER A, CURVALE G, RAOULT D: Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopaedic implants. Antimicrob. Agents Chemother. (1993) 37:1214-1218.
56. DRANCOURT M, STEIN A, ARGENSON JN, ROIRON R, GROULIER P, RAOULT D: Oral treatment of Staphylococcus spp. Infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J. Antimicrob. Chemother. (1997) 39:235-240.
57. ZIMMERLI W, WIDMER AF BLATTER M, FREI R, OCHSN PE: Role of rifampin for treatment of orthopaedic implant-related staphylococcal infections. J. Am. Med. Ass. (1998) 279:1537-1541.
58. CRICHTLEY I, GRAGHI D, SAHM D et al.: Activity of daptomycin against susceptible and multi-drug Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J. Antimicrob. Chemother. (2003) 51:639-649.
59. SENNEVILLE E, LEGOUT L, VALETT EM et al.: Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J. Antimicrob. Chemother. (2004) 54:798-802.
60. TANNENBAUM GA, POMPOSELLI FB Jr, MARCACCIO EJ et al.: Safety of vein bypass grafting to the dorsal pedal artery in diabetic patients with foot infections. J. Vasc. Surg. (1992) 15 982-990.
61. ESTES JM, POMPOSELLI FB Jr: Lower extremity arterial reconstruction in patients with diabetes mellitus. Diabet. Med. (1996) 13:S43-S47.